Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; macrogol 6000; titanium dioxide; iron oxide yellow; purified talc; polyvinyl alcohol; macrogol 3350 - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - ketraccord tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme) and, ? add-on therapy in the treatment of primary generalised tonic-clonic seizures (pgtc) in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; purified water; hypromellose; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulfonylurea failure, either alone or in combination with a sulfonylurea or as adjuvant therapy in insulin-dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; purified water; hypromellose; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulfonylurea failure, either alone or in combination with a sulfonylurea or as adjuvant therapy in insulin-dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; povidone - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulphonylurea failure, either alone or in combination with a sulphonylurea or as adjuvant therapy in insulin-dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; purified water; hypromellose; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulfonylurea failure, either alone or in combination with a sulfonylurea or as adjuvant therapy in insulin-dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; maize starch - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; polysorbate 80; crospovidone; purified talc; macrogol 6000; magnesium stearate; povidone; colloidal anhydrous silica; hypromellose - the treatment of chronic cholestatic liver diseases